{"id":"darbepoetin-dp","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-10","effect":"Thrombotic events (DVT, PE, stroke)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Injection site pain"},{"rate":"5-10","effect":"Flu-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL1201566","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darbepoetin is a hyperglycosylated analog of erythropoietin (EPO) with a longer half-life than recombinant human EPO. It activates the erythropoietin receptor on erythroid progenitor cells in the bone marrow, promoting proliferation, differentiation, and maturation of red blood cells. This mechanism is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions.","oneSentence":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:38.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Chemotherapy-induced anemia in cancer patients"},{"name":"Anemia in patients with non-myeloid malignancies"}]},"trialDetails":[{"nctId":"NCT07169643","phase":"PHASE3","title":"Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-11-25","conditions":"Liver Transplant; Complications","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Darbepoetin (DP)","genericName":"Darbepoetin (DP)","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia in cancer patients, Anemia in patients with non-myeloid malignancies.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}